Intimation to Stock Exchange
2021-2022
Audio recording of Conference Call held on May 17, 2022
May 17, 2022Outcome of Board Meeting dated 17th May, 2022
May 17, 2022Indoco’s PAT jumps 62% in Q4FY22
May 17, 2022Schedule of Con Call Meeting
May 06, 2022Board Meeting for Approval of Audited Accounts
April 22, 2022Disclosure under Regulation 30 of LODR Regulations 2015 Indoco Remedies receives USFDA approval for Lacosamide Injection USP
April 08, 2022Compliance Report on Corporate Governance {Regulation 27(2)}
April 05, 2022Disclosure under Regulation 30 of LODR Regulations 2015
Indoco Remedies receives USFDA approval for Lacosamide Tablets
March 22, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 18, 2022Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 Incorporation of a Wholly Owned Subsidiary Company
February 16, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 16, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 15, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 15, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 11, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 09, 2022Transcript of Conference Call held on February 02, 2022
February 09, 2022Audio recording of Conference Call held on February 02, 2022
February 02, 2022Publication of Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 2021
February 02, 2022Submission of Standalone & Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2021
February 01, 2022Indoco’s PAT jumps 31 % in Q3FY22
February 01, 2022Rescheduling of Con Call Meeting
January 29, 2022Intimation of Board Meeting – Unaudited Financial Results for the quarter ended December, 31, 2021
January 04, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
December 07, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
November 23, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
November 22, 2021Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (LODR) Regulations, 2015 (Listing Regulations)
November 15, 2021Submission of Standalone & Consolidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2021
November 02, 2021Indoco's EBIDTA jumps 43 % in Q2FY22
November 02, 2021Schedule of Con Call Meeting
October 22, 2021Intimation of Board Meeting - Unaudited Financial Results for the quarter/half year ended September 30, 2021
October 11, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
September 08, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
September 06, 2021Newspaper Advertisement - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
September 04, 2021Indoco's Clinical Research Organization – AnaCipher receives accreditation from UKMHRA
August 27, 2021Submission of Standalone & Consolidated Unaudited Financial Results for the First quarter ended 30th June, 2021
August 11, 2021Indoco's revenues grow at 43 %, EBIDTA jumps 78 % in Q1FY22
August 11, 2021Schedule of Con Call Meeting
July 28, 2021Credit Rating by ICRA
July 23, 2021
2020-2021
Indoco's Revenue Growth at 12%, EBIDTA Jumps 64% in Q4FY21
May 25, 2021Schedule of Con Call Meeting
May 19, 2021Board Meeting for Approval of Audited Accounts
May 03, 2021Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
March 09, 2021EBIDTA Jumps 71%, Revenue Growth @ 18% for Indoco in Q3FY21
February 09, 2021Schedule of Con Call Meeting
January 22, 2021Intimation of Board Meeting – Unaudited Financial Results for the quarter ended December, 31, 2020
January 13, 2021Closure of Trading Window
December 31, 2020Indoco wins major tenders in Germany for Allopurinol Tablets
December 08, 2020EBIDTA Doubles, Revenue Growth of 13% for Indoco in Q2FY21
November 06, 2020Schedule of Con Call Meeting
Otober 22, 2020Intimation of Board Meeting – Unaudited Financial Results for the quarter/half year ended September, 30, 2020
Otober 19, 2020Appointment of Mr. Abhijit Yashwant Gore as an Additional Independent Director of the Company
Otober 02, 2020Closure of Trading Window
September 30, 2020Retirement of Independent Director
September 30, 2020Indoco launches Fevindo 400 (Favipiravir 400mg Tablets)
September 26, 2020Indoco receives USFDA approval for Apixaban Tablets
September 14, 2020Disclosure Under Regulation 30 of LODR Regulations 2015 Credit Rating by ICRA
September 10, 2020Notice for the Seventy Third Annual General Meeting
September 01, 2020EBIDTA Doubles, Sales Grow for Indoco in Q1FY21
August 11, 2020Indoco receives USFDA approval for Olanzapine Tablets
August 06, 2020Schedule of Con Call Meeting
July 28, 2020Intimation of Board Meeting – Unaudited Financial Results for the quarter ended June 30, 2020
July 10, 2020
2019-2020
Indoco's Q4FY20 Revenues at Rs. 263 Crores
June 24, 2020Schedule of Con Call Meeting
June 04, 2020Notice of Board Meeting for Approval of Audited Accounts
June 01, 2020Disclosure under Regulation 30 of LODR Regulations 2015
April 13, 2020Closure of Trading Window
March 30, 2020Appointment of Dr. (Ms.) Vasudha V. Kamat as an Additional Independent Director of the Company
March 25, 2020Indoco's Q3FY20 revenues grow at 14.3%
January 23, 2020Schedule of Con Call Meeting
January 15, 2020Intimation of Board Meeting - Unaudited Financial Results for the quarter ended December 31,2019
January 06, 2020Indoco receives Approval for Febuxostat Tablets from USFDA
December 31, 2019Indoco receives EU GMP from UK-MHRA for its Sterile facility in Goa (Plant II)
December 16, 2019Indoco's CRO – AnaCipher receives EIR from USFDA
November 26, 2019Indoco receives EIR for its manufacturing facilities in Goa (Plant II & III)
November 25, 2019Indoco's Q2FY20 revenues grow at 21%
October 30, 2019Indoco's Clinical Research Organisation receives zero 483s from USFDA
October 18, 2019Indoco successfully concludes USFDA inspection at Goa Plant II
October 16, 2019Schedule of Con Call Meeting
October 14, 2019Intimation of Board Meeting - Unaudited Financial Results for the Quarter and half year ended September 30, 2019
October 10, 2019Indoco receives ANDA approval for Rasagiline Tablets
October 07, 2019Indoco successfully completes UK-MHRA inspection at Goa Plant II
September 23, 2019UK-MHRA reinstates full GMP status for Indoco's Goa Plant I
September 13, 2019Credit Rating by ICRA
September 03, 2019Indoco's Q1FY20 revenues grow at 16%
August 13, 2019Indoco's CRO – ANACIPHER clears USFDA inspection with ZERO 483
August 12, 2019Schedule of Con Call Meeting
August 09, 2019Schedule of Con Call Meeting
July 16, 2019Indoco's Goa Plant I receives Warning Letter from USFDA
July 15, 2019Intimation of Board Meeting - Unaudited Financial Results for the First Quarter ended 30th June, 2019
July 01, 2019Closure of Trading Window
July 01, 2019Annual Secretarial Compliance Report for Financial year ended 31.03.2019
May 27, 2019USFDA retains the OAI status of Indoco's Goa Plant I
April 24, 2019Closure of Trading Window
April 04, 2019
2018-2019
Indoco's Q4FY19 Revenues at Rs. 245 Crores
May 29, 2019Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA
March 29, 2019Indoco Q3FY19 Revenues at Rs. 248 Crores
January 23, 2019Indoco Q2FY19 Revenues at Rs. 236 Crores
November 13, 2018Indoco declares Q1FY19 results
August 13, 2018
2017-2018
Indoco's operating margins grow by 18% at Rs. 38.5 Crores
May 30, 2018Indoco's Net Profit Q-o-Q grows at 29%
January 25, 2018Indoco’s Net Profit at Rs 19.76 Crores
November 07, 2017A Double Whammy – FDA Warning Letter & GST woes for Indoco
August 09, 2017
2016-17
Indoco's Revenue for FY17 up by 9%
May 26, 2017Indoco's Net Revenues Up by 6.2%
January 27, 2017Indoco's Net Revenues Up by 11% Q-o-Q
October 26, 2016Indoco's Net Revenues Up by 16% Q-o-Q Receives ANDA approval for Allopurinol tablets
July 29, 2016